대한유전성대사질환학회지 (Journal of The Korean Society of Inherited Metabolic disease)

대한유전성대사질환학회 (The Korea Society of Inherited Metabolic Disease)
권호 표지

장쇄 지방산 산화 장애와 치료적 접근법

Long-chain Fatty Acid Oxidation Disorders and Therapeutic Approach

  • 이정현 (고신대학교복음병원 소아청소년과)
  • Lee, Jung Hyun (Department of Pediatrics, Kosin University Gospel Hospital)
  • 발행 : 2022.06.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Long-chain fatty acid oxidation disorders (LC-FAOD) are an autosomal recessive inherited rare disease group that result in an acute metabolic crisis and chronic energy deficiency owing to the deficiency in an enzyme that converts long-chain fatty acids into energy. LC-FAOD includes carnitine palmitoyltransferase type 1 (CPT1), carnitine-acylcarnitine translocase (CACT), carnitine palmitoyltransferase type 2 (CPT2), very long-chain acyl-CoA dehydrogenase (VLCAD), long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD), and trifunctional protein (TFP) deficiencies. Common symptoms of LC-FAOD are hypoketotic hypoglycemia, cardiomyopathy, and myopathy. Depending on symptom onset, the disease can be divided as neonatal period, late infancy and early childhood, adolescence, or adult onset, but symptoms can appear at any time. The neonatal screening test (NBS) can be used to identify the characteristic plasma acylcarnitine profiles for each disease and confirmed by deficient enzyme analysis or molecular testing. Before introduction of NBS, the mortality rate of LC-FAOD was very high. With NBS implementation as routine neonatal care, the mortality rate was dramatically decreased, but severe symptoms such as rhabdomyolysis recur frequently and affect the quality of life. Triheptanoin (Dojolvi®), the first drug for pediatric and adult patients with molecularly confirmed LC-FAOD, has recently been approved by the US Food and Drug Administration in 2020. In this review, the diagnosis of LC-FAOD and treatment including triheptanoin are summarized.

키워드

참고문헌

  1. Houten SM, Wanders RJ. A general introduction to the biochemistry of mitochondrial fatty acid beta-oxidation. J Inherit Metab Dis 2010;33:469-77. https://doi.org/10.1007/s10545-010-9061-2
  2. Ruiz-Sala P, Pena-Quintana L. Biochemical Markers for the Diagnosis of Mitochondrial Fatty Acid Oxidation Diseases. J Clin Med 2021;10:4855. https://doi.org/10.3390/jcm10214855
  3. Yoo HW. Inborn Errors of Mitochondrial Fatty Acid Oxidation: Overview from a Clinical Perspective. J Lipid Atheroscler 2021;10:1-7. https://doi.org/10.12997/jla.2021.10.1.1
  4. Sklirou E, Alodaib AN, Dobrowolski SF, Mohsen AWA, Vockley J. Physiological Perspectives on the Use of Triheptanoin as Anaplerotic Therapy for Long Chain Fatty Acid Oxidation Disorders. Front Genet 2021;11:598760. https://doi.org/10.3389/fgene.2020.598760
  5. Adeva-Andany MM, Carneiro-Freire N, Seco-Filgueira M, Fernandez-Fernandez C, Mourino-Bayolo D. Mitochondrial β-oxidation of saturated fatty acids in humans. Mitochondrion 2019;46:73-90. https://doi.org/10.1016/j.mito.2018.02.009
  6. Sun A, Merritt JL II. Orphan drugs in development for long-chain fatty acid oxidation disorders: challenges and progress. Orphan Drugs: Res Rev 2015;5: 33-41. https://doi.org/10.2147/ODRR.S63061
  7. Shirley M. Triheptanoin: first approval. Drugs 2020; 80:1595-600. https://doi.org/10.1007/s40265-020-01399-5
  8. Vockley J. Long-chain fatty acid oxidation disorders and current management strategies. Am J Manag Care 2020;26(7 Suppl):147-54. https://doi.org/10.37765/ajmc.2020.42784
  9. Knottnerus SJG, Bleeker JC, Wust RCI, Ferdinandusse S, IJlst L, Wijburg FA, et al. Disorders of mitochondrial long-chain fatty acid oxidation and the carnitine shuttle. Rev Endocr Metab Disord 2018;19:93-106. https://doi.org/10.1007/s11154-018-9448-1
  10. Ushikubo S, Aoyama T, Kamijo T, Wanders RJ, Rinaldo P, Vockley J, et al. Molecular characterization of mitochondrial trifunctional protein deficiency: formation of the enzyme complex is important for stabilization of both αand β-subunits. Am J Hum Genet 1996;58:979-88.
  11. Spiekerkoetter U, Lindner M, Santer R, Grotzke M, Baumgartner MR, Boehles H, et al. Management and outcome in 75 individuals with long-chain fatty acid oxidation defects: results from a workshop. J Inherit Metab Dis 2009;32:488-97. https://doi.org/10.1007/s10545-009-1125-9
  12. Williams-Hall R, Tinsley K, Kruger E, Johnson C, Bowden A, Cimms T, et al. Qualitative evaluation of the symptoms and quality of life impacts of long-chain fatty acid oxidation disorders. Ther Adv Endocrinol Metab 2022;13:20420188211065655.
  13. Shibata N, Hasegawa Y, Yamada K, Kobayashi H, Purevsuren J, Yang Y, et al. Diversity in the incidence and spectrum of organic acidemias, fatty acid oxidation disorders, and amino acid disorders in Asian countries: Selective screening vs. expanded newborn screening. Mol Genet Metab Rep 2018;16:5-10. https://doi.org/10.1016/j.ymgmr.2018.05.003
  14. Yoon HR, Lee KR, Kang S, Lee DH, Yoo HW, Min WK, et al. Screening of newborns and high-risk group of children for inborn metabolic disorders using tandem mass spectrometry in South Korea: a three-year report. Clin Chim Acta 2005;354:167-80. https://doi.org/10.1016/j.cccn.2004.11.032
  15. Merritt JL II, Norris M, Kanungo S. Fatty acid oxidation disorders. Ann Transl Med 2018;6:473. https://doi.org/10.21037/atm.2018.10.57
  16. Pena LD, van Calcar SC, Hansen J, Edick MJ, Walsh Vockley C, Leslie N, et al. Outcomes and genotype-phenotype correlations in 52 individuals with VLCAD deficiency diagnosed by NBS and enrolled in the IBEMIS database. Mol Genet Metab 2016;118:272-81. https://doi.org/10.1016/j.ymgme.2016.05.007
  17. Spiekerkoetter U, Sun B, Khuchua Z, Bennett MJ, Strauss AW. Molecular and phenotypic heterogeneity in mitochondrial trifunctional protein deficiency due to beta-subunit mutations. Hum Mutat 2003;21:598-607. https://doi.org/10.1002/humu.10211
  18. Boutron A, Acquaviva C, Vianey-Saban C, de Lonlay P, de Baulny HO, Guffon N, et al. Comprehensive cDNA study and quantitative analysis of mutant HADHA and HADHB transcripts in a French cohort of 52 patients with mitochondrial trifunctional protein deficiency. Mol Genet Metab 2011;103:341-8. https://doi.org/10.1016/j.ymgme.2011.04.006
  19. Kang E, Kim YM, Kang M, Heo SH, Kim GH, Choi IH, et al. Clinical and genetic characteristics of patients with fatty acid oxidation disorders identified by newborn screening. BMC Pediatr 2018;18:103. https://doi.org/10.1186/s12887-018-1069-z
  20. Goetzman E.S. Advances in the Understanding and Treatment of Mitochondrial Fatty Acid Oxidation Disorders. Curr Genet Med Rep 2017;5:132-42. https://doi.org/10.1007/s40142-017-0125-6
  21. Aitken-Buck HM, Krause J, Zeller T, Jones PP, Lamberts RR. Long-Chain Acylcarnitines and Cardiac Excitation-Contraction Coupling: Links to Arrhythmias. Front Physiol 2020;11:1174. https://doi.org/10.3389/fpls.2020.01174
  22. Longo N, Amat di San Filippo C, Pasquali M. Disorders of Carnitine Transport and the Carnitine Cycle. Am J Med Genet C Semin Med Genet 2006;142:77-85.
  23. Bennett M.J. Pathophysiology of Fatty Acid Oxidation Disorders. J. Inherit. Metab Dis 2010;33:533-37. https://doi.org/10.1007/s10545-010-9170-y
  24. Karall D, Brunner-Krainz M, Kogelnig K, Konstantopoulou V, Maier EM, Moslinger D, et al. Clinical outcome, biochemical and therapeutic follow-up in 14 Austrian patients with long-chain 3-hydroxy acyl coa dehydrogenase deficiency (LCHADD). Orphanet J Rare Dis 2015;10:21. https://doi.org/10.1186/s13023-015-0236-7
  25. Lotz-Havla AS, Roschinger W, Schiergens K, Singer K, Karall D, Konstantopoulou V, et al. Fatal pitfalls in newborn screening for mitochondrial trifunctional protein (MTP)/long-chain 3-hydroxyacyl-coa dehydrogenase (LCHAD) deficiency. Orphanet J Rare Dis 2018;13:122 https://doi.org/10.1186/s13023-018-0875-6
  26. Shekhawat PS, Matern D, Strauss AW. Fetal fatty acid oxidation disorders, their effect on maternal health and neonatal outcome: impact of expanded newborn screening on their diagnosis and management. Pediatr Res 2005;57(5 Pt 2):78R-86R. https://doi.org/10.1203/01.pdr.0000159631.63843.3e
  27. Spikerkoetter U. Mitochondrial fatty acid oxidation disorders: clnical presentation of long chain fatty acid oxidation defects before and after newborn screening. J Inherit Metab Dis 2010:33:527-32. https://doi.org/10.1007/s10545-010-9090-x
  28. https://www.acmg.net/ACMG/Medical-Genetics-PracticeResources/ACT_Sheets_and_Algorithms.aspx.
  29. Lindner M, Hoffmann GF, Matern D. Newborn screening for disorders of fatty-acid oxidation: experience and recommendations from an expert meeting. J Inherit Metab Dis 2010;33:521-6. https://doi.org/10.1007/s10545-010-9076-8
  30. Wanders RJA, Visser G, Ferdinandusse S, Vaz FM, Houtkooper RH. Mitochondrial fatty acid oxidation disorders: laboratory diagnosis, pathogenesis, and the complicated route to treatment. J Lipid Atheroscler 2020;9:313-33. https://doi.org/10.12997/jla.2020.9.3.313
  31. Aldubayan SH, Rodan LH, Berry GT, Levy HL. Acute illness protocol for fatty acid oxidation and carnitine disorders. Pediatr Emerg Care 2017;33:296-301 https://doi.org/10.1097/PEC.0000000000001093
  32. DaTorre SD, Creer MH, Pogwizd SM, Corr PB. Amphipathic lipid metabolites and their relation to arrhythmogenesis in the ischemic heart. J Mol Cell Cardiol 1991;23 Suppl 1:11-22.
  33. Spiekerkoetter U, Lindner M, Santer R, Grotzke M, Baumgartner MR, Boehles H, et al. Treatment recommendations in long-chain fatty acid oxidation defects: consensus from a workshop. J Inherit Metab Dis 2009;32:498-505. https://doi.org/10.1007/s10545-009-1126-8
  34. Yamada K, Taketani T. Management and diagnosis of mitochondrial fatty acid oxidation disorders: focus on very-long-chain acyl-CoA dehydrogenase deficiency. J Hum Genet 2019;64:73-85. https://doi.org/10.1038/s10038-018-0527-7
  35. Zand D, Doan J, Yi S, Wang J, Ma L, Akinshola E, et al. Regulatory news: Dojolvi (triheptanoin) as a source of calories and fatty acids in long-chain fatty acid oxidation disorders: FDA approval summary. J Inherit Metab Dis 2021;44:515-7. https://doi.org/10.1002/jimd.12377
  36. Roe CR, Roe DS, Wallace M, Garritson B. Choice of oils for essential fat supplements can enhance production of abnormal metabolites in fat oxidation disorders. Mol Genet Metab 2007;92:346-50. https://doi.org/10.1016/j.ymgme.2007.07.012
  37. Merritt JL 2nd, MacLeod E, Jurecka A, Hainline B. Clinical manifestations and management of fatty acid oxidation disorders. Rev Endocr Metab Disord 2020; 21:479-93. https://doi.org/10.1007/s11154-020-09568-3
  38. Shah ND, Limketkai BN. The use of medium-chain triglycerides in gastrointestinal disorders. Practical Gastro. Published February 2017. Accessed May 20, 2020. med.virginia.edu/ginutrition/wp-content/uploads/sites/199/2014/06/Parrish-February-17.pdf.
  39. Vockley J, Burton B, Berry GT, Longo N, Phillips J, Sanchez-Valle A, et al. UX007 for the treatment of long chain-fatty acid oxidation disorders: safety and efficacy in children and adults following 24 weeks of treatment. Mol Genet Metab 2017;120:370-77. https://doi.org/10.1016/j.ymgme.2017.02.005
  40. Marin-Valencia I, Good LB, Ma Q, Malloy CR, Pascual JM. Heptanoate as a neural fuel: energetic and neurotransmitter precursors in normal and glucose transporter I-deficient (G1D) brain. J Cereb Blood Flow Metab 2013;33:175-82. https://doi.org/10.1038/jcbfm.2012.151
  41. Gillingham MB, Heitner SB, Martin J, Rose S, Goldstein A, El-Gharbawy AH, et al. Triheptanoin versus trioctanoin for long-chain fatty acid oxidation disorders: a double blinded, randomized controlled trial. J Inherit Metab Dis 2017;40:831-43. https://doi.org/10.1007/s10545-017-0085-8
  42. Vockley J, Burton B, Berry GT, Longo N, Phillips J, Sanchez-Valle A, et al. Results from a 78-week, single-arm, open-label phase 2 study to evaluate UX007 in pediatric and adult patients with severe long-chain fatty acid oxidation disorders (LC-FAOD). J Inherit Metab Dis 2019;42:169-77. https://doi.org/10.1002/jimd.12038
  43. Vockley J, Burton B, Berry G, Longo N, Phillips J, Sanchez-Valle A, et al. Effects of triheptanoin (UX007) in patients with long-chain fatty acid oxidation disorders: Results from an open-label, long-term extension study. J Inherit Metab Dis 2021;44:253-63. https://doi.org/10.1002/jimd.12313